Earnings call
Jubilant Ingrevia Q1 FY26 earnings call: Jubilant Ingrevia was in discussion with key accounts for almost 70 plus different opportunities and hoped many would start materializing in coming quarters
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company was in discussion with key accounts for almost 70 plus different opportunities and hoped many would start materializing in coming quarters. The company completed the plant modification for its first key agro CDMO order and started deliveries in Q1 FY’26 using a First Time Right approach. Specialty Chemicals segment revenue grew 11% year-on-year in Q1 FY’26 on account of higher sales from fine chemicals and CDMO businesses. The company doubled its U.S. business in FY’25 versus FY’24 and said it was focusing heavily on the U.S.; its opportunities were spread across the EU, U.S. and Japan, where it had gained traction and new opportunities in the last one year. The company was hopeful that 70%-80% of the 70 opportunities in its sales funnel would materialize over time, subject to external factors and customers' own plans.
The numbers management gave
Results
- Specialty Chemicals segment revenue grew 11% year-on-year in Q1 FY’26 on account of higher sales from fine chemicals and CDMO businesses.
Show source
Let me start with Specialty Chemicals: During the quarter, the Specialty Chemicals segment’s revenue grew 11% on year- on-year basis on account of higher sales coming from fine chemicals and CDMO businesses.
- Specialty Chemicals segment achieved its highest-ever EBITDA of Rs. 130 Crore and an EBITDA margin of 27% in Q1 FY’26.
Show source
During the quarter, Specialty Chemicals once again achieved its highest ever EBITDA of Rs. 130 Crore and the EBITDA margin of 27%.
- EBITDA was Rs. 153 crore in Q1 FY’26, up 29% year-on-year, primarily driven by margin improvements in Specialty Chemicals and Nutrition and cost optimization initiatives.
Show source
The EBITDA for the quarter was Rs. 153 crore, reflecting a 29% rise on a year-on-year basis.
- PAT was Rs. 75 crore in Q1 FY’26, compared with Rs. 49 crore in Q1 FY’25, an increase of 54% year-on-year.
Show source
The PAT for the quarter was Rs. 75 crore as against Rs. 49 crore in Q1 FY’25, witnessing an increase of 54% on a year-on-year basis.
- The company said Pyridine and Picoline were driven more by scale and cost, and that it aimed to protect market share and keep its plants at 80% plus utilization by continuously optimizing its cost structure.
Show source
We run our plants at 80% capacity utilization in Pyridine and Picoline.
- Pharma funnel doubled in the last one year, with the company mostly interacting with innovators and tier 1 CDMOs in Europe and US.
Show source
There is pharma where as I said in my opening remarks, our funnel has just doubled in the last one year with all the push we have given and mostly we are interacting with innovators and tier 1 CDMOs in Europe and US.
Show 6 more statements
Results
- Specialty and Nutrition together account for close to 90% of overall company-level EBITDA, and Specialty accounts for close to 65%-70% plus.
Show source
Now, Specialty and Nutrition together are close to 90% and Specialty is I think close to 65%-70% plus.
- U.S. revenue grew 11% year-over-year and its Rest of the World (ROW) revenue grew 45% year-over-year, primarily driven by strong performance in Specialty Chemicals and Nutrition.
Show source
As a result, we are witnessing a notable increase in revenue contribution from the U.S and Rest of the World markets, with the U.S. revenue growing by 11% year- over-year and Rest of the World revenue surging by an impressive 45% year-over- year.
Money and capital
- Net debt was Rs. 700 crore as on 30th June, and its net debt to EBITDA ratio was 1.18x, calculated on the basis of trading 12 months EBITDA.
Show source
The net debt of the company as on 30th June was Rs. 700 crore and the net debt to EBITDA ratio remained stable at 1.18x, calculated on the basis of trading 12 months EBITDA.
- The company incurred around Rs. 54 crore of capital expenditure in Q1 FY’26, mainly for the upcoming CDMO agro plant at Bharuch and primarily funded through internal accruals.
Show source
The capital expenditure incurred during the quarter was around Rs. 54 crore, which was mainly utilized towards the upcoming CDMO agro plant at Bharuch and was primarily funded through internal accruals.
- The company planned to invest Rs. 600 crore in CAPEX in FY’26.
Show source
In FY’26, we planned to invest Rs. 600 crore in CAPEX.
- The company had invested Rs. 2000 crore, and the Rs. 2000 crore investment would be completed later in the year with the dedicated plant being built at Bharuch for the big agro contract.
Show source
We have invested Rs. 2000 crore and with the dedicated plant that we are building in Bharuch for the big agro contract, that Rs. 2000 crore will get completed later this year.
What it expects ahead
What management expects
- The company was in discussion with key accounts for almost 70 plus different opportunities and hoped many would start materializing in coming quarters.
Show source
And linking it back to the other comment I made in my opening remarks, we are in discussion with our key accounts for almost 70 plus different opportunities and we are hopeful many of them will start materializing in coming quarters.
- The company maintained that the peak potential of its investment was around Rs. 6500 crore depending on pricing, and expected to get closer to that number in FY’27 once the CAPEX was fully utilized.
Show source
And we maintain that view that from today, once all of this CAPEX gets fully utilized and hopefully in FY’27, we will get closer to that number.
- The company hoped to utilize 70%-80% of the capacity built through its Rs. 2000 crore investment by the end of FY’27.
Show source
But we do hope to utilize the capacity built through this Rs. 2000 crore to be almost 70%-80% utilized by end of FY’27.
- The company has seen upticks in Acetyl segment volumes for 6 to 8 quarters, particularly in agro chemicals applications for acetic anhydride and some industrial segments for ethyl acetate, and hopes volumes will hold up, remain competitive, maintain or grow its market share, and improve margins through cost initiatives.
Show source
And with that, we are hopeful that margins should improve.
- The company hopes to grow its nutrition business 20%-25% year-on-year.
Show source
Putting together, we do hope to grow this business at 20%-25% year-on-year, which is what we have communicated in investor day as well.
- The company hopes its announced projects and prior investments will provide enough capacity in its system to serve its FY’27 target.
Show source
So, these are the four or five major ones and these along with what we have already invested and announced in the past as I was saying earlier, we are hopeful that the target that we have for FY’27 will have enough capacity in our system to serve that.
Show 13 more statements
What management expects
- The company hopes Specialty will account for at least 65%-70% of overall company-level EBITDA in steady state, even after Acetyls bounces back.
Show source
So, we do hope that in steady state even after Acetyls bounces back which we are hoping in next few quarters as we were just discussing, Specialty will be at least at 65%-70% of our overall company level EBITDA.
- The company has 12 odd semiconductor molecules in different stages, has sent samples for many, and hopes they will move into commercial stage in the near future; it does not expect a big revenue impact from them in the next few quarters.
Show source
Deepak Jain: Yes, so I just responded to the previous question, we have 12 odd molecules in different stages, many of them we have sent samples too and we are hoping they will move into commercial stage in near future even though we don't expect a big impact on revenue coming from these in the next few quarters because these are at least customers in the initial stages.
- The company expects revenue to CAPEX ratios of at least 1.2 to 1.3x and sometimes 1.4 to 1.5x for the investments discussed.
Show source
Now, to the broad sense I can say that at least revenue level, we expect 1.2 to 1.3x at least and sometimes even 1.4 to 1.5x on the revenue to CAPEX ratio.
- The company started exporting a CDMO product in this quarter and hopes its full potential in the next couple of years will be at least 4-5x what it will do this year.
Show source
So, because we never disclose any specific information related to our CDMO products, but what I can say is this product, the one which we have started to export in this quarter, we are hopeful that in next couple of years, the full potential will be at least 4-5x of what we will do this year.
- The company set a target of annualised savings exceeding Rs 100+ crore in FY26 under its Lean 2.0 cost optimisation program and progressed well in Q1; Jubilant Ingrevia has indicated INR100 crore per year in cost savings under Lean 2.0 and is firmly on track; Jubilant Ingrevia's lean savings program of INR100 crore plus per annum remains on track, driving efficiency across the value chain.
Show source
As part of our Lean 2.0 cost optimization program, we have set a target of achieving annualized savings exceeding Rs 100+ crore in FY’26, and have progressed well in Q1.
- The company was working to get its Choline Chloride product ready for the European Union and hoped its first shipments would go to Europe within the next couple of weeks.
Show source
We are already working on getting our product ready for European Union and we are hopeful that within the next couple of weeks, our first shipments will go to Europe.
- The company said there were at least five to six more opportunities beyond two announced last year in October, with a couple in advanced stages, and it hoped to receive more confirmations in coming months or a couple of quarters.
Show source
There are at least five to six more.
- The company expects its food and cosmetic segment to grow as its new plant commissioned in March stabilizes and is filled with new orders from a couple of marquee customers, with growth expected to accelerate.
Show source
So, for the food and cosmetic segment, we expect that to grow and with the new plant which got commissioned in March and is now stabilizing, we are hoping the growth will accelerate as we fill up that plant with new orders from a couple of marquee customers.
- Feed segment has been volatile between price and volume, but the company hopes it will stay stable over the long term and expects to grow food-grade Niacin volume significantly with the US market opening up.
Show source
The feed segment has been volatile, those of you who have been tracking us there between price and volume, there is always some volatility but we hope that from a long-term trend perspective, it will stay stable and with the US market opening up for us, particularly for food grade on Niacin, we Page 15 of 20 hope to grow volume significantly there.
- The company expects to grow its nutrition portfolio through specialty and exports growth, following lower domestic prices and significantly higher Choline, B4 volume versus last year.
Show source
At this stage, we feel the combination of specialty and exports growth which I responded to Siddharth's first question on European, we should be able to grow that portfolio as well.
- The company recently started its human nutrition business and hopes it will provide upside in the next couple of quarters.
Show source
And third is we have recently started the human nutrition business and the rest should start hopefully to give us some upside in next couple of quarters.
- The company hopes specialty and export growth will more than offset negative effects from feed-segment volatility and chlorine chloride prices.
Show source
The combined effect of all of that, we are hoping the negative forces which come because of the volatility in the feed segment and prices of chlorine chloride will get more than offset by the growth in our specialty as well as the export growth.
- The company hopes to see a step change in its food and cosmetic segment in the next couple of quarters. Replaced by a later filing.
Show source
So, hopefully in next couple of quarters, we will see a step change coming from there.
What it is building and selling
Projects and capacity
- The company completed the plant modification for its first key agro CDMO order and started deliveries in Q1 FY’26 using a First Time Right approach.
Show source
We successfully completed the plant modification for our first key agro CDMO order, and started the deliveries with a First Time Right approach in Q1 FY’26.
- New boiler at its Bharuch facility was scheduled for commissioning in Q2 of FY’26, with more than 99% of the work completed.
Show source
The commissioning of the new boiler at our Bharuch facility is scheduled for Q2 of FY’26, with more than 99% work already completed.
- The company is debottlenecking existing multi-purpose plants in Bharuch and Gajraula to create at least 15% to 20% additional capacity to serve its immediate requirement.
Show source
Thirdly, we have existing multi-purpose plants in both Bharuch and Gajraula which we are debottlenecking and creating at least 15% to 20% additional capacity to serve our immediate requirement.
- Of the Rs. 2000 crore Jubilant Ingrevia invested, 70% went into specialty, mostly to create multipurpose or dedicated plants serving its CDMO and Fine Chemicals businesses; many multipurpose plants are used interchangeably for Fine Chemicals and CDMO.
Show source
Deepak Jain: Harsh, so as we have been saying of the Rs. 2000 crore we invested, 70% of that has gone into specialty and most of it has gone into creating multipurpose plants or dedicated plants to serve our CDMO and Fine Chemicals businesses.
- Capex execution remains on track for the $300 million big Agro contract, and the company expects to start supplies early 2026.
Show source
Also, CAPEX execution remains on track for the $300 million big Agro contract, and we expect to start the supplies early 2026.
- Debottlenecking initiatives were underway to unlock additional capacity across its Diketene and Pyridine platforms.
Show source
In addition, debottlenecking initiatives are actively underway to unlock additional capacity across our core platforms, including Diketene and Pyridine.
Show 15 more statements
Projects and capacity
- The company commenced detailed engineering work for a new multi-purpose plant at its Gajraula site.
Show source
We have also commenced detailed engineering work for a new multi-purpose plant at our Gajraula site, further reinforcing our commitment to expanding capabilities and supporting long-term demand.
- The company expects to start construction of the new multi-purpose plant at its Gajraula site in the next few months.
Show source
We expect to start the construction in next few months for this plant.
- New multi-purpose plant at Gajraula will serve several product categories in its fine chemicals and CDMO portfolio, is not dedicated to a particular contract, and is being planned in anticipation of products and volumes expected in core and new product categories over the next year or so.
Show source
No, it is not a dedicated plant for any particular contract, but it is in anticipation of the products and the volumes we are expecting in some of our core as well as new product categories in the next year or so.
- The company had seven existing multi-purpose plants serving its CDMO and fine chemicals businesses from Gajraula.
Show source
Very much similar to the way our seven existing multipurpose plants serve our CDMO and fine chemicals business from Gajraula today.
- The company is creating a dedicated plant in Bharuch, expected to be completed by the end of this year.
Show source
So, obviously as I said earlier, there is a big dedicated plant we are creating in Bharuch which will get completed hopefully by end of this year.
- The company expects to fire its boiler project within the next month or two.
Show source
Second is the boiler project which also we are expecting to fire within next month or two.
- The company has started detailed engineering for MPP8, a multi-purpose plant in Gajraula, and hopes to start construction in the next couple of months; it is also changing its niacinamide plant, commissioned in March, into a multi-purpose plant for the human nutrition segment.
Show source
Fourth is the MPP8 which I mentioned the multi-purpose plant in Gajraula which should, the detailed engineering has already started and we are hoping to start the construction in the next couple of months and on our niacinamide plant also, which we commissioned in March, we are doing some changes to convert it into a multi-purpose plant for the human nutrition segment.
Demand and pricing
- The company doubled its U.S. business in FY’25 versus FY’24 and said it was focusing heavily on the U.S.; its opportunities were spread across the EU, U.S. and Japan, where it had gained traction and new opportunities in the last one year.
Show source
To your second question, the opportunities are spread across the three geographies which I mentioned in my opening comments, which are EU, which has been a traditionally strong market for us, US, where we are focusing very heavily and we have doubled our business in FY’25 versus FY’24, and Japan, where we are relatively new, but we Page 12 of 20 have gotten very good traction in the last one year there and we are getting new opportunities from there as well.
- The company said initial information from different sources indicated a European Choline Chloride market of tens of thousands of tons.
Show source
While we are still getting a sense of the overall market, the initial numbers we have gathered from different sources run into tens of thousands of tons of market in Europe.
- The company said European Choline Chloride realizations would be better than India, and it hoped the existing premium over Indian prices would increase after duties were imposed, but it did not specify the premium's exact quantum.
Show source
We are in touch with the customers, so I don't want to speculate the prices right now, but definitely the realizations will be better than India.
- The company said it had some price advantage in the US market relative to Chinese competitors and sometimes obtained a price premium in specific European market segments, particularly for Picoline.
Show source
We do have some price advantage, particularly in the US market, where we are sweetly placed vis-a-vis Chinese.
Segments
- The company was hopeful that 70%-80% of the 70 opportunities in its sales funnel would materialize over time, subject to external factors and customers' own plans.
Show source
Currently, there are over 70 high-priority opportunities being actively pursued within the sales funnel, reflecting robust market interest and potential for future growth.
- Semiconductor molecules are high value and low volume products focused on the synthesis part of the value chain.
Show source
Besides that of course, I can't disclose what kind of molecules they are, but these are high value and low volume products and focus on synthesis part of the value chain.
Deals and partners
- The company announced two agro-segment contracts last year; it served revenues against one in this quarter, expects the second to start early 2026, and has another half a dozen in various stages of discussions.
Show source
The agro-segment as you would probably know, there are only four or five big customers, we are in touch with all of them and like I said in response to one of the questions, we announced two contracts last year, one of which we served the revenues against it in this quarter Page 16 of 20 and the second one hopefully will start early 2026 and there are another half a dozen which are in various stages of discussions.
- The company said it was in advanced stages of discussions with customers for most of the products planned for its new multi-purpose plant, which was being designed for flexibility to accommodate multiple products.
Show source
For most of them, we are already in advanced stages of discussions with the customers and we are building or at least conceptualizing right now the plant in a way that there is enough fungibility in the plant to fit in multiple products as per the need.
Risks, rules and outside factors
Outside factors
- The European Union put a 125% duty on Chinese Choline Chloride, opening an opportunity for Jubilant Ingrevia.
Show source
Recently, European Union has put a 125% duty on Chinese Choline Chloride, which opens up an opportunity for us.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Siddharth Gadekar: Hi sir, good evening. So, the first question is on Choline Chloride. Can you give some sense on with this anti-dumping duty on China, what kind of opportunities this can open for us and what kind of volumes and pricing delta that we can see in this segment?
Answer, deepak jain
Deepak Jain: Yes, thank you Siddharth. That's a good question and definitely an opportunity that we are very excited about. Choline Chloride, as you may know, is a core product in our portfolio. We have been doing it for several years now and we are the market leader in India with more than 50% share and we have been exporting it to other markets as well. Recently, European Union has put a 125% duty on Chinese Choline Chloride, which opens up an opportunity for us. While we are still getting a sense of the overall market, the initial numbers we have gathered from different sources run into tens of thousands of tons of market in Europe. We are already working on getting our product ready for European Union and we are hopeful that within the next couple of weeks, our first shipments will go to Europe.
Answer, deepak jain
Once the product is accepted by the market, we are hoping we will be able to scale it up. Like we have created a leadership position for ourselves for Vitamin B3 in the European market, we are hopeful that in Vitamin B4, which is Choline Chloride also in Europe, we will be able to build a leadership position for ourselves in the coming years.
Question
Siddharth Gadekar: Just on the realization difference, what could be the realization difference between India and Europe because of this anti-dumping duty?
Answer, deepak jain
Deepak Jain: It's too early to say that, Siddharth. What we do know is before the duties were put, there was already a premium that European market was paying to Choline Chloride versus what the prices in India are. With the duties being put, we are hopeful that the premium will only increase. The exact quantum of that, we will know once we start sending materials to the customers. We are in touch with the customers, so I don't want to speculate the prices right now, but definitely the realizations will be better than India. Page 9 of 20 Siddharth Gadekar: Sir, secondly, the multipurpose plant that you spoke about, can you give some sense of what kind of CAPEX that we would be doing for the new multipurpose plant?
Question
Is this for the new customer or contract that we would be looking to sign up? Or we are just setting up capacities in anticipation of the demand?
Answer, deepak jain
Deepak Jain: As I mentioned in my opening remarks, this is a multipurpose plant and that by definition will be serving several product categories in our fine chemicals as well as CDMO portfolio. Very much similar to the way our seven existing multipurpose plants serve our CDMO and fine chemicals business from Gajraula today. No, it is not a dedicated plant for any particular contract, but it is in anticipation of the products and the volumes we are expecting in some of our core as well as new product categories in the next year or so. For most of them, we are already in advanced stages of discussions with the customers and we are building or at least conceptualizing right now the plant in a way that there is enough fungibility in the plant to fit in multiple products as per the need. And linking it back to the other comment I made in my opening remarks, we are in discussion with our key accounts for almost 70 plus different opportunities and we are hopeful many of them will start materializing in coming quarters. So, we want to be ready with capacity as we get confirmations from our customers.
Question
Pradeep Thakur: Good evening. Thank you for the opportunity. My question is, during the recent investor meet, the company had guided the additional Rs. 2000 crore investment that you would have done. You would reach a peak revenue of Rs. 8000 crore by FY’27. Does the management still maintain this outlook, sir?
Answer, deepak jain
Deepak Jain: So, Pradeep, you are right. We have invested Rs. 2000 crore and with the dedicated plant that we are building in Bharuch for the big agro contract, that Rs. 2000 crore will get completed later this year. But the peak potential of that, I think even in the Page 10 of 20 investor day, was not Rs. 8000 crore, but we had said around Rs. 6500 crore depending on the pricing. And we maintain that view that from today, once all of this CAPEX gets fully utilized and hopefully in FY’27, we will get closer to that number. But as I mentioned in the investor, a lot depends on pricing as well because in certain segments, pricing is still volatile and has not come back completely. So, let's see how prices come back. But we do hope to utilize the capacity built through this Rs. 2000 crore to be almost 70%-80% utilized by end of FY’27.
Answer, deepak jain
Deepak Jain: So, that we are working on them and obviously we announced two last year in October. There are at least five to six more. I have been updating all of you in these quarterly calls. A couple of them are in advanced stages. It also depends on the global macro environment which has just started to turn around. So, we are hopeful in coming months or couple of quarters we will get more confirmations. But we are in constant touch with the customers.
Question
Pradeep Thakur: Last question, sir. Now that you are seeing demand coming back in most of your segments, how confident are you that this demand will not fade away and there would be a meaningful recovery?
Answer, deepak jain
Deepak Jain: So, Pradeep, obviously like chemical business goes through cycles and we are coming out of a very deep negative cycle. And if you look at segment by segment agrochemical volumes, you look at the results of the MNCs as well as our Indian peers, we are seeing improvement in volumes. In pharma also, there is stability in volumes and prices are holding up. Nutrition is also by and large holding up the volume. So, given that, it's been almost 7-8 quarters of low volumes. Acetyls also by the way, as Varun mentioned in his notes, there is some increase in volumes in the last quarter. So, we are hopeful that we are coming out of the deep drop we were in.
Answer, deepak jain
Obviously, if some other external global event happens or if the tariff Page 11 of 20 situation moves against us, not just as a country but as an industry, then anything can happen. But at least at this stage, based on the indications we have from our customers, based on the results we are seeing of our peers as well as customers and our own volumes in different segments, we are hopeful that this will be a more sustained recovery. The pace of which of course varies depending on which segment you're talking about.
Question
Rohit Nagraj: Thanks for the opportunity. The first question is the 70 molecules pipeline that you talked about. So, two parts, one is what is the kind of addressable market for these molecules? And second, is there any particular geography that we are concentrating either in terms of import substitution or maybe certain markets like Europe or so? So, just a little clarity on this would be helpful. Thank you.
Answer, deepak jain
Deepak Jain: Yes, so I think while I will not give specific numbers, but what I can say is given that these 70 opportunities we have, we have kind of created by engaging deeply with our key accounts, 30-plus key accounts over the last two years, these are reasonably scaled opportunities. And at an overall level, the overall addressable market will run into thousands of crore. Now, of course, they are at different stages of maturity in our sales funnel. I'm hopeful that over a period of time, 70%-80% of that will materialize, but we will see. As I said earlier, it also depends on a lot of external factors, customers' own plans. But at this stage, we are quite well poised and we are doing everything from our side to give comfort and confidence to our customers that we are the right partner for these opportunities. To your second question, the opportunities are spread across the three geographies which I mentioned in my opening comments, which are EU, which has been a traditionally strong market for us, US, where we are focusing very heavily and we have doubled our business in FY’25 versus FY’24, and Japan, where we are relatively new, but we Page 12 of 20 have gotten very good traction in the last one year there and we are getting new opportunities from there as well.
Question
Rohit Nagraj: Thanks. Sir, second question, in terms of Pyridine Picoline, where we have a global leadership position. In terms of the pricing, do we not have any material advantage given that we are the largest producer and we can dictate the prices to some extent, similar to what Chinese players usually do? Do we not have that kind of an advantage here? If not, what deters us in terms of the pricing volatility? Is it predominantly demand led or are there any other factors? Thank you Deepak Jain: We are the leader, as you rightly said.
Answer, deepak jain
We run our plants at 80% capacity utilization in Pyridine and Picoline. We do have some price advantage, particularly in the US market, where we are sweetly placed vis-a-vis Chinese. We do get some price premium sometimes in the European market also for specific segments, particularly for Picoline. But I think that segment is driven more by our scale and cost because we continuously keep working on the cost structure and keep optimizing it and hence our imperative as well as intent there is always to ensure we protect our market share and run our plants at 80% plus utilization. So, while we do have some power to command premium, particularly in markets like US and for certain specific applications in that segment, our focus is always to maximize our volumes and keep our cost structure linear.
Question
Rohan Mehta: Hello sir. Thank you so much for the opportunity. So, I wanted to understand what percentage of ethyl acetate in terms of is part of your chemical intermediates revenue? That's the first question and secondly, on the entire chemical intermediates space, I think we saw a bounce back in terms of EBITDA margins. Last quarter, you reported at about 2.5% to 3% margins and this quarter it's been better. Page 13 of 20 Have you seen that that bottom now has been made and prices can at least stabilize in the interim at these levels?
Answer, deepak jain
Deepak Jain: So, to the first question, Rohan, unfortunately, I will not be able to give you specific numbers, but all I would say because we never disclose product-level numbers externally, but what I can say is ethyl acetate is a key product in our portfolio along with acetic anhydride, the two products together form bulk of our acetyl segments and we are pushing hard on both and we have significant share of the market in particularly domestic market for both the products and we intend to protect that position and we have been growing volumes in both in the last few quarters, as I said in my opening remarks. To the second question, yes, we are hopeful. Acetyl has gone through a long low cycle now, almost 6 to 8 quarters and we have seen some uptick in volumes, particularly and applications in agro chemicals for acetic anhydride and some of the industrial segments for ethyl acetate, so we are hopeful that volumes will hold up now and as that happens and with all the cost initiatives we have taken to optimize our cost structure for both the products, we hope to continue to be competitive in the market and maintain our share if not grow it further. And with that, we are hopeful that margins should improve.
Answer, deepak jain
Now, of course, that market is volatile so anything can happen within a week's time but looking at the fundamentals, the growth coming back in the key segments of agrochem as I was saying as well as pharma and some of the consumer segments where these two chemicals go, we are hopeful that we have seen the worst and we are coming out of it. The pace of recovery could be slower than what we have seen in the past for this product at least based on the initial indications that I have heard from our customers but let's see, I think we will have to see for another quarter or two, how this pans out and whether the volumes hold up or not to be able to draw any meaningful conclusion on the long-term trajectory.
Question
Rohan Mehta: My second question is I think one of your domestic competitors in the Acetyl space actually reported worsening EBITDA on this front. So, I'm just trying to understand was it purely the acetic acid prices which helped you or apart from your lean initiatives was there something more to the margins jumping? Page 14 of 20 Deepak Jain: See, I will not be able to comment on any other player's performance, but regarding our business it's a combination like I said, our volumes have grown so that has clearly given us the scale.
Answer, deepak jain
Our cost initiatives we have been continuously working on so that are helping us as well. Pricing has been muted in fact sometimes or most times, it has acted negatively especially versus last year. On a quarter-to-quarter basis, I think it's been pretty stable if I remember correctly. So, it's largely driven by the volume increase as well as the cost initiatives.
Question
Junail Shaikh: Good evening, Deepak. Firstly, I'd like to applaud the team for what you guys communicated on Spec Chem and you guys have been very consistent on the profit margins in that division. My question is on the choline side, as obviously the last four quarters in the nutrition segment, we have been in that Rs. 180-Rs. 185 crore run rate. I just wanted to see in the short term at least around 12 months out, what can we expect out there? I know you commented on that, but at least in the next 12 months if you can talk about certain expectations that'll be great.
Answer, deepak jain
Deepak Jain: Yes, so nutrition segment there are various forces acting on that portfolio and then part of it, we had explained in our investor day presentation also in February. So, on one side, we have our core Vitamin B3 portfolio which has both feed and now increasingly growing nonfeed segment which served food and cosmetic segment. So, for the food and cosmetic segment, we expect that to grow and with the new plant which got commissioned in March and is now stabilizing, we are hoping the growth will accelerate as we fill up that plant with new orders from a couple of marquee customers. So, hopefully in next couple of quarters, we will see a step change coming from there. The feed segment has been volatile, those of you who have been tracking us there between price and volume, there is always some volatility but we hope that from a long-term trend perspective, it will stay stable and with the US market opening up for us, particularly for food grade on Niacin, we Page 15 of 20 hope to grow volume significantly there. The second component of that is our Choline, B4 segment where unfortunately prices have gone down significantly in domestic market, but we have increased the volume significantly versus last year and we are building a specialty portfolio which will again drive growth.
Answer, deepak jain
At this stage, we feel the combination of specialty and exports growth which I responded to Siddharth's first question on European, we should be able to grow that portfolio as well. And third is we have recently started the human nutrition business and the rest should start hopefully to give us some upside in next couple of quarters. The combined effect of all of that, we are hoping the negative forces which come because of the volatility in the feed segment and prices of chlorine chloride will get more than offset by the growth in our specialty as well as the export growth. Putting together, we do hope to grow this business at 20%-25% year-on-year, which is what we have communicated in investor day as well.
Show 5 more questions
Question
Junail Shaikh: Thanks Deepak and good luck. Thank you.
Answer, deepak jain
Deepak Jain: Surabhi, we have three parts to our CDMO business and some of this information we had shared in our investor day presentation in February which is publicly available including the number of molecules in each of the three sub-segments at that stage. That will give you a good sense but there are three parts. There is pharma where as I said in my opening remarks, our funnel has just doubled in the last one year with all the push we have given and mostly we are interacting with innovators and tier 1 CDMOs in Europe and US. The agro-segment as you would probably know, there are only four or five big customers, we are in touch with all of them and like I said in response to one of the questions, we announced two contracts last year, one of which we served the revenues against it in this quarter Page 16 of 20 and the second one hopefully will start early 2026 and there are another half a dozen which are in various stages of discussions.
Answer, deepak jain
Semicon is nascent for us as well as for India as an industry Indian chemical industry, but we have a dozen of semiconductor related CDMO opportunities which most of which we have supplied the samples for and we are hopeful some of them will convert into commercial opportunities, but initially we expect very little revenues from them because these are still early days for semiconductor chemicals for us as well as for the industry and customers are still testing waters here. Surabhi: Got it. Thank you.
Question
Siddharth Gadekar: I have one more question on the CAPEX. So, what sort of projects are in the pipeline currently in terms of the plans that we are likely to put up in this year?
Answer, deepak jain
Deepak Jain: So, Siddharth, part of it is the flow over on the Rs. 2000 crore plant we had announced. So, obviously as I said earlier, there is a big dedicated plant we are creating in Bharuch which will get completed hopefully by end of this year. That is the major one. Second is the boiler project which also we are expecting to fire within next month or two. Thirdly, we have existing multi-purpose plants in both Bharuch and Gajraula which we are debottlenecking and creating at least 15% to 20% additional capacity to serve our immediate requirement. Fourth is the MPP8 which I mentioned the multi-purpose plant in Gajraula which should, the detailed engineering has already started and we are hoping to start the construction in the next couple of months and on our niacinamide plant also, which we commissioned in March, we are doing some changes to convert it into a multi-purpose plant for the human nutrition segment. So, these are the four or five major ones and these along with what we have already invested and announced in the past as I was saying earlier, we are hopeful that the target that we have for FY’27 will have enough capacity in our system to serve that.
Question
Shreya Banthia: Thanks for the opportunity. As we have reported a strong growth share of the specialty segment, so how do you see these on a sustainable basis, what would be the contribution from the specialty chemicals to the overall EBITDA going forward?
Answer, deepak jain
Deepak Jain: Shreya, so specialty segment if you observe, our business over the last eight quarters, it has increased significantly. Now, Specialty and Nutrition together are close to 90% and Specialty is I think close to 65%-70% plus. So, we do hope that in steady state even after Acetyls bounces back which we are hoping in next few quarters as we were just discussing, Specialty will be at least at 65%-70% of our overall company level EBITDA. Shreya Banthia: So, could you give us some sense on the semiconductor opportunity, the molecules that are developing?
Answer, deepak jain
Deepak Jain: Yes, so I just responded to the previous question, we have 12 odd molecules in different stages, many of them we have sent samples too and we are hoping they will move into commercial stage in near future even though we don't expect a big impact on revenue coming from these in the next few quarters because these are at least customers in the initial stages. We are just testing quarters and once they get comfortable, we are hopeful that they will start giving revenues. Besides that of course, I can't disclose what kind of molecules they are, but these are high value and low volume products and focus on synthesis part of the value chain.
Question
Harsh Mehta: So, my first question was what kind of CAPEX is being done for the CDMO business and in the last call, you had mentioned that majority of CAPEX that I want to understand in the CDMO business, what kind of gross returns to assets, what kind Page 18 of 20 of margins and what kind of working capital cycle will be there for the CDMO business?
Answer, deepak jain
Deepak Jain: Harsh, so as we have been saying of the Rs. 2000 crore we invested, 70% of that has gone into specialty and most of it has gone into creating multipurpose plants or dedicated plants to serve our CDMO and Fine Chemicals businesses. Many of the multipurpose plants are used interchangeably to serve our fine chemicals and CDMO plants. Now, to the broad sense I can say that at least revenue level, we expect 1.2 to 1.3x at least and sometimes even 1.4 to 1.5x on the revenue to CAPEX ratio. The rest of it of course, varies so much based on specific products and their profile that it is hard to generalize.
Question
Harsh Mehta: And sir, one more question was that there is a new product that you started to export, if I am not wrong the key ingredient to produce pyronaridine, anti-malarial 44.37, the average revenue per unit for this particular intermediate was $300 plus. So, I wanted to understand how big can this opportunity be for the company?
Answer, deepak jain
Deepak Jain: So, I will neither confirm nor deny what you said. So, because we never disclose any specific information related to our CDMO products, but what I can say is this product, the one which we have started to export in this quarter, we are hopeful that in next couple of years, the full potential will be at least 4-5x of what we will do this year.
Questions about this call
- When was the Jubilant Ingrevia Q1 FY26 earnings call transcript filed?
- Jubilant Ingrevia filed the transcript with the exchange on 6 Aug 2025. This page is built from that transcript.
- What does this page list?
- 53 statements from the transcript across 8 topics, 32 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 15 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.